PALO ALTO, Calif., Feb. 5, 2014 /PRNewswire/ -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that CEO Jeffrey K. Tong, Ph.D., is scheduled to present at the following conferences in February:
- 16th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York on Tuesday, Feb. 11, 2014 at 8:45 a.m. (EST).
- Leerink Global Healthcare Conference 2014 at the Waldorf Astoria in New York on Wednesday, Feb. 12, 2014 at 8:25 a.m. (EST).
About Nora Therapeutics, Inc.
Nora Therapeutics is a privately-held biotechnology company focused on developing therapeutics to address IVF failure and recurrent pregnancy loss, two reproductive conditions with significant unmet need. Nora's lead compound, NT100, is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract and may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. For more information, please visit our website at www.noratherapeutics.com.
SOURCE Nora Therapeutics